the plural and correlatives thereof, are defined in the
applicable Sections of this Agreement.
Defined Term Section "Acquiring Party"
Section 14.2 "ADR"
Section 13.2(a)
"Advanced CUT Female Product Costs"
Section 3.2 "Additional Activities"
Section 1.8(a) "Additional Light-Based Hair Management Product"
Section 1.7
"Additional Product Report"
Section 1.7 "Agreement"
Preamble "Annual
Exclusivity Collaboration Payment"
Section 6.1(g) "Annual Exclusivity
Collaboration Period"
Section 6.1(g) "Authorized Overruns"
Section
1.8(a)(i)(2) "Commencement Date"
Section 1.1(c)
-xv-
Defined Term Section "Commercial Assessment Period Additional Activities"
Section 2.2(a) "Confidential Information"
Section 9.3(a) "Cure Period"
Section 10.3 "CUT Female Product"
Section 3.1(a) "CUT Product Specifications"
Section 3.1(b) "Delivery Date"
Section 3.1(c) "Development Completion
Payments"
Section 6.1(d)(i) "Disclosure Schedule"
Section 12.1 "Dispute"
Section 13.1 "Dispute Notice"
Section 12.3(a)(i) "Effective Date"
Preamble
"Estimate"
Section 1.8(a)(2) "Evaluation Materials"
Section 5.1(b)(ii)
"Exclusivity Payment Date"
Section 6.1(g) "Failure to Launch Payments"
Section 2.1(b)(ii) "Female Product Payment Rate"
Section 6.1(h) "First
Development Completion Payment"
Section 6.1(d)(i) "First Press Release"
Section 9.5 "Gillette"
Preamble "Gillette Controlled Information"
Section
9.1(c) "Gillette Exclusive Licenses"
Section 8.3(a)(i) "Gillette Exclusive
License Period"
Section 8.3(a)(i) Gillette License Agreement
Section
5.3(b)(i) Gillette Licensee
Section 5.3(b)(i) "Indemnification Claim Notice"
Section 11.3(a) "Indemnified Party"
Section 11.3(a) "Independent Product
Payment Rate"
Section 6.4 "Infringement Suit"
Section 8.5(c)(i) "Initial
Gillette Specifications"
Section 5.4(a)(i)(1) "Initial R&D Plan"
Section
1.1(a) "In-License Agreement"
Section 12.3(f) "Invoiced Sales"
Definition of
"Net Sales" "Launch Decision"
Section 2.3 "Licensed Palomar Patents"
Section
12.3(f) "Female Product Payment Rate"
Section 6.1(h) "Palomar"
Preamble
"Losses"
Section 11.1 "Male Collaboration Agreement"
Section 5.1(c) "Male
Option"
Section 5.1(a) "Male Product"
Section 5.1(a) "Male Product
Opportunity"
Section 5.1(b) "Manufacturing Cost"
Section 3.2 "Manufacturing
Fee"
Section 3.2
-xvi-
Defined Term Section "MGH Joint Invention"
Section 8.1(c)(ii)(2) "MGH Joint
Know-How"
Section 8.1(c)(ii)(2) "MGH Joint Patents"
Section 8.1(c)(ii)(2)
"MGH Joint Technology"
Section 8.1(c)(ii)(2) "Neutral"
Section 13.2(a)
"Non-Disclosure Agreement"
Section 9.8 "Non-Product Components"
Definition
of Net Sales "Offer"
Section 10.1(b) "Offer Period"
Section 10.1(b)
"Opportunity Notice"
Section 5.1(b) "Opportunity Notice Effective Date"
Section 5.1(b)(iii) "Option Exercise Notice"
Section 5.1(b)(iv) "Option
Exercise Period"
Section 5.1(b)(iv) "Overrun"
Section 1.8(a)(2) "Owned
Palomar Patents"
Section 12.3(f) "Palomar Controlled Information"
Section
9.1(b) "Palomar Exclusive Licenses"
Section 8.4(b)(iii) "Palomar Exclusive
License Period"
Section 8.4(b)(iii) "Palomar Key Personnel"
Section 1.1(d)
"Palomar License Agreement"
Section 5.3(a)(i) "Palomar Licensee"
Section
5.3(a)(i) "Palomar Marks"
Section 2.1(a)(iii)(2) "Palomar Medical
Technologies, Inc."
Preamble "Palomar U.S. Regulatory Documentation"
Section
1.2(e) "Permitted Confidants"
Section 9.1(a) "Product/Service Payment Rate"
Section 6.5 "R&D Advance Payment"
Section 6.1(b) "R&D Payments"
Section
6.1(a) "R&D Committee"
Section 1.4(a) "R&D Committee Chair"
Section 1.4(c)
"R&D Committee Leader"
Section 1.4(b) "R&D Leader"
Section 1.1(d) "R&D
Period"
Section 1.1(c) "R&D Plan"
Section 1.1(a) "R&D Plan Subcontracted
Activities"
Section 1.1(e) "SEC"
Section 9.5 "Second Development Completion
Payment"
Section 6.1(d)(i) "Subject Male Product"
Section 5.1(b)(1)
"Supplemental R&D Plan"
Section 1.7 "Supplemental R&D Payments"
Section 1.7
"Ten-Day Notice"
Section 3.1(a) "Terms and Conditions"
Section 13.2(b) "The
Gillette Company"
Preamble "Third Party Claim"
Section 11.1
-xvii-
Defined Term Section "Total CUT Supply"
Section 3.1(c)
-xviii-
Exhibit A
R&D Plan
** This material has been